Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 193

Results For "Health"

4192 News Found

Evonik launches GMP-quality plant-based squalene
News | November 08, 2023

Evonik launches GMP-quality plant-based squalene

PhytoSquene now available for clinical and commercial use


Indian pharmaceutical companies have become reliable and affordable suppliers of high-quality drugs: MoS Bhagwant Khuba
Policy | November 08, 2023

Indian pharmaceutical companies have become reliable and affordable suppliers of high-quality drugs: MoS Bhagwant Khuba

Lack of technology transfer stands out as a formidable barrier


Lupin Mandideep plant gets USFDA green signal
Drug Approval | November 01, 2023

Lupin Mandideep plant gets USFDA green signal

The inspection of the facility conducted from August 7 to August 11, 2023


Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru
Biotech | October 31, 2023

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution


Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India
News | October 31, 2023

Sun Pharma to co-market Zydus’s CKD treatment drug ‘Desidustat’ in India

The drug will be marketed by Sun Pharma under the brand name RYTSTAT


Lubrizol launches carbopol polymers for nutraceuticals with new EU good grade approval
News | October 31, 2023

Lubrizol launches carbopol polymers for nutraceuticals with new EU good grade approval

The European Commission approved the use of Carbopol as an additive for liquid and solid food supplements in the EU


EnginZyme produces key mRNA vaccine ingredient using biocatalysis
Biotech | October 30, 2023

EnginZyme produces key mRNA vaccine ingredient using biocatalysis

2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines


Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19
News | October 30, 2023

Pfizer and BioNTech announce data for mRNA-based vaccine program for influenza and COVID-19

The companies plan to start a pivotal Phase 3 trial in the coming months


USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent
Drug Approval | October 26, 2023

USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent

The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer